Revumenib as Pre-Emptive Therapy for Measurable Residual Disease in NPM1-mutated or KMT2A-rearranged AML: a Domain of the Multi-Arm ALLG AMLM26 INTERCEPT Platform Trial

Abstract | Dec 7, 2024

Author

Loo S, et al.

Congress

American Society of Hematology Annual Meeting 2024

San Diego, California | Dec 7 – 10, 2024